Literature DB >> 3361908

Treatment response and safety of ambulatory medical detoxication.

A I Alterman1, M Hayashida, C P O'Brien.   

Abstract

An ambulatory medical detoxication program for alcoholics with limited social and environmental supports is described. The treatment response of all 49 patients who underwent treatment and the short-term outcome and safety of 15 patients (31%) who failed to complete treatment are reviewed. Treatment completers were found to attend over 90% of their scheduled daily appointments and drinking during the treatment term was infrequent. The average duration for completed treatments was approximately 5 appointment days. Treatment noncompleters also attended their scheduled appointments regularly prior to discontinuation and, except for several patients who were transferred to inpatient treatment because of continued drinking, drinking during detoxication was relatively infrequent. The short-term outcome and safety of treatment noncompleters was reviewed. No instance of serious medical or psychiatric consequences following discontinuation from treatment was revealed. It was concluded that discontinuation of treatment by a patient is not in all cases indicative of a poor outcome. It was further concluded that ambulatory medical detoxication is a relatively successful treatment for mild to moderate alcohol withdrawal symptomatology and for patients not requiring immediate medical or psychiatric attention.

Entities:  

Mesh:

Year:  1988        PMID: 3361908     DOI: 10.15288/jsa.1988.49.160

Source DB:  PubMed          Journal:  J Stud Alcohol        ISSN: 0096-882X


  2 in total

1.  Utilization of acute inpatient services for alcohol detoxification.

Authors:  B M Booth; F C Blow; R L Ludke; R L Ross
Journal:  J Ment Health Adm       Date:  1996

2.  The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial.

Authors:  R Malcolm; H Myrick; J Roberts; W Wang; R F Anton; J C Ballenger
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.